Reaction
Catheter Site Inflammation reporting signals
As of the last recalculation, Catheter Site Inflammation appears in 545 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is EPOPROSTENOL (PRR 420.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Epoprostenol | 114 | 420.3 | 424.0 |
| Teduglutide | 19 | 55.8 | 55.8 |
| Ado-Trastuzumab Emtansine | 10 | 46.1 | 46.2 |
| Macitentan | 60 | 37.1 | 37.1 |
| Bosentan | 41 | 33.5 | 33.5 |
| Tadalafil | 75 | 33.0 | 33.0 |
| Sildenafil | 44 | 31.5 | 31.5 |
| Sildenafil Powder, | 27 | 30.4 | 30.5 |
| Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose | 6 | 28.3 | 28.3 |
| Sildenafil Citrate | 80 | 28.0 | 28.0 |
| Treprostinil | 77 | 27.1 | 27.1 |
| Ambrisentan | 68 | 23.6 | 23.6 |
| Riociguat | 19 | 23.0 | 23.0 |
| Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride | 17 | 21.5 | 21.6 |
| Atezolizumab | 10 | 10.0 | 10.0 |